Company intelligence / Profile preview
Sagesse Bio
unknown, Delaware, United Statessagessebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sagesse Bio’s lead compound, SGY‑101, is an siRNA-based therapeutic targeting TGF‑β1 and COX‑2 for localized fat reduction. The drug is IND-enabled and currently in Phase II clinical trials for other indications. Early human studies have shown good tolerability with evidence of adipocytolysis. The company aims to address unmet needs in noninvasive body contouring and tissue remodeling within aesthetic medicine
- Therapeutic areas
- Dermatology
- Modalities
- Small interfering RNARNAi-based drugsNanoparticle (histidine-lysine nanoparticle delivery)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sirnaomics Ltd.Gore Range Capital LLC
Beyond the preview
Go deeper on Sagesse Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sagesse Bio.